ChromaDex to Present at the Zooming with LD Virtual Investor Conference
ChromaDex Corp. (NASDAQ:CDXC) today announced that its Chief
Executive Officer, Rob Fried, and Chief Financial Officer, Kevin
Farr, will be presenting virtually at the Zooming with LD investor
The ChromaDex management team is scheduled to present on
Thursday, March 25, 2021 at 12:30 p.m. Eastern Time (9:30 a.m.
The presentation will be webcast live via the link below on the
investor relations section of the Company’s website at
www.chromadex.com. ChromaDex management will also attend virtual
one-on-one meetings with institutional investors throughout the
day. For those interested in having a meeting with ChromaDex please
visit www.ldmicro.com for more information.
Webcast link: ChromaDex Investor Presentation – Zooming with
View ChromaDex’s profile here:
ChromaDex Corp. is a global bioscience company dedicated to
healthy aging. The ChromaDex team, which includes world-renowned
scientists, is pioneering research on nicotinamide adenine
dinucleotide (NAD+), levels of which decline with age. ChromaDex is
the innovator behind NAD+ precursor nicotinamide riboside (NR),
commercialized as the flagship ingredient Niagen®. Nicotinamide
riboside and other NAD+ precursors are protected by ChromaDex’s
patent portfolio. ChromaDex delivers Niagen® as the sole active
ingredient in its consumer product Tru Niagen® available at
www.truniagen.com and through partnerships with global retailers
and distributors. ChromaDex maintains a website at
www.chromadex.com to which ChromaDex regularly posts copies of its
press releases as well as additional and financial information
about the Company.
About LD Micro
LD Micro aims to be the most important resource in the micro-cap
world. Whether it is the index, comprehensive data, or hosting the
most influential events on an annual basis, LD's sole mission is to
be invaluable for all those interested in finding the next
generation of great companies.
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities and Exchange Act of 1934, as
amended. Statements that are not a description of historical facts
constitute forward-looking statements and may often, but not
always, be identified by the use of such words as "expects,"
"anticipates," "intends," "estimates," "plans," "potential,"
"possible," "probable," "believes," "seeks," "may," "will,"
"should," "could" or the negative of such terms or other similar
expressions. More detailed information about ChromaDex and the risk
factors that may affect the realization of forward-looking
statements is set forth in ChromaDex's Annual Report on Form 10-K
for the fiscal year ended December 31, 2020, ChromaDex's Quarterly
Reports on Form 10-Q and other filings submitted by ChromaDex to
the SEC, copies of which may be obtained from the SEC's website at
www.sec.gov. Readers are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
hereof, and actual results may differ materially from those
suggested by these forward-looking statements. All forward-looking
statements are qualified in their entirety by this cautionary
statement and ChromaDex undertakes no obligation to revise or
update this release to reflect events or circumstances after the
version on businesswire.com: https://www.businesswire.com/news/home/20210318005256/en/
ChromaDex Investor Relations Contact: Brianna Gerber,
Vice President of Finance and Investor Relations 949-419-0288 ext.
ChromaDex Media Contact: Alex Worsham, Vice President of
Global Marketing and Communications 310-388-6706 ext. 689
Historical Stock Chart
From Jun 2021 to Jul 2021
Historical Stock Chart
From Jul 2020 to Jul 2021